Diagnosis → Type and stage of cancer (Complexity of therapeutic protocol, duration of treatment, early vs. advanced stage ...)

Availability of oral anticancer treatment?

YES → Bioequivalence between oral and IV drugs (evidence)?

YES → Approved label use

NO → Treatment available only in oral form

NO → Oral treatment available through a clinical trial

NO → Off label use which could be monitored by early access program, clinical trial or guidelines

NO → Physician clinical experience/background and experience in prescribing OADs

Patient's preference for oral route

NO → IV treatment may be relevant

YES → Concordance between physician & patient on the treatment objectives and ways to achieve it (dialogue)

Evaluation of patient's profile and his environment (which may influence adherence)

<table>
<thead>
<tr>
<th>Age</th>
<th>Performance status</th>
<th>Cognitive functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-morbidities and poly-medications (risk of drug interactions)</td>
<td>Patient autonomy (Involvement in disease management, ability to spontaneously report adverse events ...)</td>
<td></td>
</tr>
<tr>
<td>Familial supporting</td>
<td>Professional and social environment (active, retirement ...)</td>
<td></td>
</tr>
<tr>
<td>Geographical environment and access to healthcare services (rural or urban area, coordination between hospital and community services, availability of a therapeutic education program ...)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>